News & Updates

Infliximab trumps other biologics as maintenance drug in CD
Infliximab trumps other biologics as maintenance drug in CD
19 Feb 2025 byStephen Padilla

Among the many biologics used to treat adults with moderate-to-severe Crohn’s disease (CD), infliximab subcutaneous (SC) 120 mg every 2 weeks (Q2W) demonstrates the highest efficacy in clinical remission during maintenance treatment of 52 to 64 weeks’ duration, according to the results of a recent study presented at CCC 2025.

Infliximab trumps other biologics as maintenance drug in CD
19 Feb 2025
DOACs for ICH survivors with atrial fibrillation? Stroke protection comes at a cost
DOACs for ICH survivors with atrial fibrillation? Stroke protection comes at a cost
14 Feb 2025 byJairia Dela Cruz

For survivors of intracerebral haemorrhage (ICH) with atrial fibrillation (AF), the use of direct oral anticoagulants (DOACs) works to prevent ischaemic stroke events, but this benefit appears to be offset by major bleeding side effects, as shown in the open-label, phase III PRESTIGE-AF trial.

DOACs for ICH survivors with atrial fibrillation? Stroke protection comes at a cost
14 Feb 2025